Your shopping cart is empty

Subscriber login

Advanced Search

Home
Books
Conferences
DVDs
Newsletters
Form 483s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us

Check out our free and informative ezines and sign up now

Home > Newsletters > Drug Industry Daily > Unapproved Ophthalmic Drugs Draw Warnings for Akorn, Bausch + Lomb

Drug Industry Daily

Oct. 10, 2012 | Vol. 11 No. 199

Unapproved Ophthalmic Drugs Draw Warnings for Akorn, Bausch + Lomb

Akorn and Bausch + Lomb (B+L) have received warning letters from the FDA for marketing unapproved ophthalmic drugs containing pilocarpine hydrochloride at various strengths.

This article is viewable by subscribers only. To view this article, please select an option below.

Subscribe
Print This Page
Email This Article
RSS
Free Trial
Archives
Sample PDF

Baxter Warned About Mold, GMP Deviations at Two Plants FDA Warns Indian Drug, API Maker for Deleting and Backdating Records Baxter Warned Over Contamination, GMP Deviations at Two Plants Sandoz Subsidiary Warned for Specification Inspection Snafus

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.